Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $223000.0.

  • Rani Therapeutics Holdings' Depreciation & Amortization (CF) fell 1389.96% to $223000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $980000.0, marking a year-over-year decrease of 91.0%. This contributed to the annual value of $1.0 million for FY2024, which is 2506.08% up from last year.
  • As of Q3 2025, Rani Therapeutics Holdings' Depreciation & Amortization (CF) stood at $223000.0, which was down 1389.96% from $240000.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Depreciation & Amortization (CF) high stood at $266000.0 for Q4 2024, and its period low was $111000.0 during Q1 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $189947.4, with a median of $189000.0 in 2023.
  • Per our database at Business Quant, Rani Therapeutics Holdings' Depreciation & Amortization (CF) tumbled by 1838.24% in 2022 and then skyrocketed by 6936.94% in 2023.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Depreciation & Amortization (CF) stood at $113000.0 in 2021, then soared by 53.98% to $174000.0 in 2022, then soared by 30.46% to $227000.0 in 2023, then grew by 17.18% to $266000.0 in 2024, then dropped by 16.17% to $223000.0 in 2025.
  • Its last three reported values are $223000.0 in Q3 2025, $240000.0 for Q2 2025, and $251000.0 during Q1 2025.